Adaptive Biotechnologies vs CRISPR Therapeutics

Adaptive Biotechnologies (ADPT), health care, and CRISPR Therapeutics (CRSP), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Adaptive Biotechnologies is worth $4.6B on the stock market and CRISPR Therapeutics $3.9B: Adaptive Biotechnologies is valued at 18% more. Adaptive Biotechnologies's operating margin in its latest fiscal year was -20.6% and CRISPR Therapeutics's -18934%. Over the past year Adaptive Biotechnologies's share price has moved +103% and CRISPR Therapeutics's -24.5%.

Key facts

Adaptive Biotechnologies market value
$4.6B
CRISPR Therapeutics market value
$3.9B
Adaptive Biotechnologies revenue
$277MFY to 2025-12-31
CRISPR Therapeutics revenue
$3.5MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Adaptive Biotechnologies vs CRISPR Therapeutics: every measure side by side
Measure Adaptive Biotechnologies CRISPR Therapeutics
SectorHealth CareHealth Care
Country United States Switzerland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$4.6Bhigher$3.9Blower
Revenue$277Mhigher$3.5Mlower
Earnings-$59.5Mhigher-$581.6Mlower
Employees624—
Total assets$512.7Mlower$2.3Bhigher
Valuation
P/E——
P/S16.7lower1110higher
P/B26.1—
Dividend yield0.00%—
Profitability
Operating margin-20.6%higher-18934%lower
Balance sheet
Net assets$218.8Mlower$1.9Bhigher
Total liabilities$287.7Mlower$343.4Mhigher
Total debt$131.2M—
Cash on hand$70.5Mlower$347.6Mhigher
Price change
Today+2.22%higher-0.54%lower
1 year+103%higher-24.5%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Adaptive Biotechnologies only (2)

CRISPR Therapeutics only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Adaptive Biotechnologies / CRISPR Therapeutics). Who owns ADPT · Who owns CRSP

Further comparisons

Learn

Questions and answers

Which is bigger, Adaptive Biotechnologies or CRISPR Therapeutics?

By market value, Adaptive Biotechnologies is the larger: $4.6B against $3.9B for CRISPR Therapeutics. By revenue in its latest fiscal year, Adaptive Biotechnologies is the larger: $277M against $3.5M for CRISPR Therapeutics.

Which has the higher operating margin?

Adaptive Biotechnologies: -20.6%, against -18934% for CRISPR Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Adaptive Biotechnologies and CRISPR Therapeutics?

In their latest 13F filings, Cathie Wood holds both.

Cite this page

Funkfolio, “Adaptive Biotechnologies vs CRISPR Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/adpt-vs-crsp

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.